FibroBiologics receives HREC approval for Phase 1/2 trial for CYWC628

FibroBiologics (FBLG) announced that it has received both public and private Human Research Ethics Committee, HREC, approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers, DFU. This approval enables enrollment of 120 patients at 10 sites across Australia. With the HREC approval and Therapeutics Goods Administration, TGA, filing now complete, FibroBiologics has secured all necessary regulatory approvals and submitted all required filings to proceed with the clinical trial.